On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol
- 1 May 1992
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 57 (5) , 974-979
- https://doi.org/10.1016/s0015-0282(16)55011-0
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Nafarelin versus danazol in the treatment of endometriosisAmerican Journal of Obstetrics and Gynecology, 1990
- What is the source of elevated serum levels of CA 125 in patients with endometriosis?European Journal of Obstetrics & Gynecology and Reproductive Biology, 1989
- CA 125 levels in endometriosis patients before, during and after treatment with Danazol or LHRH agonistsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1989
- Endometriosis: treatment with gonadotropin-releasing hormone agonist BuserelinFertility and Sterility, 1989
- Serum CA-125 antigen levels increase during mensesAmerican Journal of Obstetrics and Gynecology, 1987
- Elevated serum concentrations of CA-125 in patients with advanced endometriosisFertility and Sterility, 1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Danazol for the Treatment of Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 1983
- Tissue Distribution of a Coelomic- Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC125International Journal of Gynecological Pathology, 1983
- Classification of EndometriosisFertility and Sterility, 1979